The Maternal Fetal Screen^SM | T1

Excellent clinical utility

Ability to order NIPT as an add-on or reflex—or in combination with biochemical screening—reduces diagnostic timeline, streamlines ordering and resulting process, and eliminates added visits for blood draws.

NTD Eurofins offers both biochemical and cell-free fetal DNA screening test options.

• NTD offers biochemical + NIPT test options
• All specimens drawn at initial visits
• Saves time in the testing process
• Convenient and hassle-free for patients (no return visits)

Performed between 10 weeks, 0 days and 13 weeks, 6 days gestation, the test combines ultrasound markers with the analysis of five biological markers to increase the detection rates and assess risk  for:

Chromosomal  Abnormalities

The chromosome abnormalities screened for in this test including:

• Trisomy 21 (Down syndrome)
• Trisomy 18 (Edwards Syndrome)
• Trisomy 13 (Patau syndrome)

Optional Early Onset Preeclampsia (EOPE)

Early onset preeclampsia is defined as preeclampsia resulting in the delivery of the fetus before 34 weeks’ gestation. It is estimated to occur in approximately 0.5% of all pregnancies. Early onset preeclampsia is less common than the late form of the disorder, but contributes more to the morbidity and mortality of pregnant mothers and babies.

NTD also offers stand -alone preeclampsia screening that does not include a risk assessment for Down syndrome, Trisomy 18 (Edwards Syndrome), or Trisomy 13 (Patau syndrome).

Learn more about our Preeclampsia Screen^SM | T1

Optional Fetal Sex Assessment

Y chromosome assessment is now an option available to patients who are pregnant with singletons that will assess the fetal sex of a singleton pregnancy.

Fetal Sex Assessment now available with MaternalFetalScreen | T1®

Using real-time PCR technology, MaternalFetalScreen | T1® detects the presence of Y chromosome. This information is incorporated into the analyte MoM calculation, providing a more personalized risk assessment than ever before.

How? Using MoM adjustment factors allows individual analyte values to be compared to populations with similar clinical factors. Previous studies have shown differences in the median level of certain analytes based on fetal sex. The result of this added evaluation will further refine the risk analyses for Down syndrome, Trisomy 18, Trisomy 13 and early onset preeclampsia.

Optional Other Obstetric Complications

By analyzing the biochemical markers in patient’s blood, Maternal Fetal Screen^SM | T1 casts a wide net and also offers insight into  other maternal and fetal issues, such as aneuploidy, low birth weight, fetal loss, and stillbirth.

*Information provided if second trimester screening is included

Learn more about how to opt-in for prenatal report flags.

Detection Rates

Test Results

Turn around time:

MaternalFetalScreen | T1® results can be expected 2-5 days from the time the sample is received at the laboratory.

Turn around time is 3-6 days when adding the additional EOPE test option.

Turnaround time for reflex option is 6 days post reporting positive MaternalFetalScreen | T1® result.

Early Detection, Early Assurance with Instant Risk Assessment from eReports

First Trimester Screen^SM | Fß with Instant Risk Assessment from eReports enables physicians to present a complete risk assessment for Down syndrome and Trisomy 18 (Edwards Syndrome) and Trisomy 13 (Patau syndrome) during a single office visit and ensure same-day results notification for the patient. As early as 10 weeks gestation, a maternal blood sample can be collected and submitted to NTD. The results of the blood screen are maintained and made available to the physician when the patient undergoes her nuchal ultrasound exam between 11 weeks, 1 day and 13 weeks, 6 days of gestation. To save time, NTD provides web-based access to your patient’s biochemistry data through a secure eReports website.

View the complete list of references